News Releases

News Releases

Keyword Search

Date Title  
11/21/22
Optinose Announces Pricing of Public Offering of Common Stock and Warrants
Printer Friendly Version
11/21/22
Optinose Announces Proposed Public Offering of Common Stock and Warrants
Printer Friendly Version
11/10/22
Optinose Reports Third Quarter 2022 Financial Results and Operational Updates
Printer Friendly Version
11/09/22
Optinose Announces ReOpen2 Presentation at the American College of Asthma, Allergy, and Immunology (ACAAI) 2022 Annual Scientific Meeting
Printer Friendly Version
11/07/22
Optinose Announces Reporting Date for Third Quarter 2022 Financial Results
Printer Friendly Version
10/21/22
Optinose Announces Late Breaking Abstract Podium Presentation at IDWeek 2022
Printer Friendly Version
09/06/22
Optinose Announces ReOpen1 Abstract Selected for Presentation at the American Rhinologic Society Annual Meeting
Printer Friendly Version
08/11/22
Optinose Reports Second Quarter 2022 Financial Results and Operational Updates
Printer Friendly Version
08/08/22
Optinose Announces Reporting Date for Second Quarter 2022 Financial Results
Printer Friendly Version
07/13/22
Optinose Announces that XHANCE Significantly Reduced Incidence of Exacerbations for Patients with Chronic Sinusitis in Landmark ReOpen Program
Printer Friendly Version
07/08/22
Optinose Announces Additional Positive Results from ReOpen2 and Initial Results from Pooled Analyses of Both Trials in the ReOpen Program
Printer Friendly Version
06/13/22
Optinose Announces Positive Top-line Results of ReOpen2, its second Phase 3 Clinical Trial of XHANCE for Treatment of Chronic Sinusitis
Printer Friendly Version
06/03/22
Optinose Announces Departure of Chief Financial Officer
Printer Friendly Version
05/12/22
Optinose Reports First Quarter 2022 Financial Results and Operational Updates
Printer Friendly Version
05/05/22
Optinose Announces Reporting Date for First Quarter 2022 Financial Results
Printer Friendly Version
04/26/22
Optinose Announces Appointment of R. John Fletcher to the Board
Printer Friendly Version
04/08/22
Optinose to Present at the Needham Virtual Healthcare Conference
Printer Friendly Version
03/08/22
Optinose Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights
Printer Friendly Version
03/07/22
Optinose Reports Positive Top-line Results in ReOpen1, a Landmark Phase 3 Trial for XHANCE in Chronic Sinusitis
Printer Friendly Version
03/04/22
Optinose Announces Reporting Date for Fourth Quarter 2021 Financial Results
Printer Friendly Version

Investors


Toolkit